NCT03590223

Glycosylated Hemoglobin and Risk of Perioperative Major Cardiovascular Events in Diabetic Patients Undergoing Coronary Bypass Revascularization (HbA1c)

Glycosylated Hemoglobin and the Risk of Perioperative Major Cardiovascular Events in Diabetic Patients Undergoing Coronary Bypass Revascularization

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 589 (actual)
• Sponsor: University Hospital, Basel, Switzerland · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Glycosylated Hemoglobin (HbA1c) is considered as one of the best markers to assess the glycaemia treatment over a period of 3 to 4 months, and is considered as predictive marker for perioperative mortality and morbidity. The impact of the elevated HbA1c on the risk of perioperative major cardiovascular events in patients undergoing coronary bypass revascularization (by retrospective analysis of perioperative cardiovascular events and preoperative HbA1c) is evaluated.

Conditions

• Cardiovascular Event
• Coronary Artery Bypass Graft
• Diabetes Mellitus

Interventions

Type	Name	Description
PROCEDURE	Coronary Bypass Revascularization	analysis of perioperative major cardiovascular events in diabetic patients

Timeline

• Start date: 2017-12-29
• Primary completion: 2018-08-21
• Completion: 2018-08-21
• First posted: 2018-07-18
• Last updated: 2021-04-01

Locations

1 site across 1 country: Switzerland